Gulf Pharmaceutical Industries and BMG Pharma S.r.l are pleased to announce a partnership for the commercialization of proprietary technology products in women’s health under the BMG Ginoxil brand in the Middle East and Africa. Under the terms License and Supply Agreement, Julphar will exclusively register and commercialize BMG’s highly innovative gynecology products.
The Agreement will enable Julphar to rapidly introduce this innovative women’s health portfolio in a fast growing and largely self-payment driven market. These products have been developed to address major unmet needs for patients and physicians in the evolving MEA market. Julphar expects to launch this family of products directly from early 2014 onwards.
Commenting on the agreement, Julphar CEO Dr Ayman Sahli said: “Julphar is proud to partner with BMG on this new line of products. This union is the result of a shared goal of increasing access to high-quality medicines. Looking at the current MEA market demands, we are confident this will fill a gap in the existing market and add major value to women’s health in the region.”
“We believe this partnership with Julphar, a leading company in the MEA countries, with whom we share vision and values, is key to growing sales of BMG’s women’s health products. BMG’s proven innovation capabilities complements Julphar’s deep understanding of the evolving needs in MEA’s healthcare market”, said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l.
“This long-term partnership is a major milestone for BMG as it opens us the door to one of the most exciting healthcare market in the world.”
###